

NCI TABLE 2: LEO/MER Subcohort Patient Characteristics by Subtype. U01 CA195568-06 Progress Report (2/1/2022)
LEO/MER Subcohort cases consented 9/1/2002 to 6/30/2015 (Data lock: 6/01/2021)

Characteristics	DLBCL (N=1374)	FL (N=1167)	MCL (N=341)	MZL (N=526)	Other B- cell (N=612)	Other NHL (N=211)	T-cell (N=447)	Composites (N=227)	Total (N=4905)
Age @ Enrollment									
Mean (SD)	61.0 (15.84)	59.3 (13.23)	64.7 (11.07)	62.0 (12.51)	61.4 (14.69)	59.2 (13.62)	57.1 (16.06)	62.2 (12.40)	60.6 (14.34)
Median	63	60	64	63	63	60	59	64	62
IQR	52.0, 72.0	51.0, 68.0	57.0, 73.0	54.0, 71.0	53.0, 72.0	50.0, 68.0	46.0, 69.0	53.0, 71.0	52.0, 71.0
Range	18.0, 95.0	19.0, 93.0	32.0, 96.0	18.0, 92.0	18.0, 91.0	18.0, 86.0	18.0, 95.0	21.0, 87.0	18.0, 96.0
Gender									
Male	776 (56.5%)	620 (53.1%)	263 (77.1%)	234 (44.5%)	379 (61.9%)	125 (59.2%)	268 (60.0%)	143 (63.0%)	2808 (57.2%)
Female	598 (43.5%)	547 (46.9%)	78 (22.9%)	292 (55.5%)	233 (38.1%)	86 (40.8%)	179 (40.0%)	84 (37.0%)	2097 (42.8%)
Ethnicity									
Non-Hispanic/Latinx	1188 (86.5%)	1030 (88.3%)	307 (90.0%)	468 (89.0%)	529 (86.4%)	197 (93.4%)	385 (86.1%)	196 (86.3%)	4300 (87.7%)
Hispanic/Latinx	12 (0.9%)	15 (1.3%)	2 (0.6%)	6 (1.1%)	4 (0.7%)	1 (0.5%)	8 (1.8%)	3 (1.3%)	51 (1.0%)
Unknown/not reported	174 (12.7%)	122 (10.5%)	32 (9.4%)	52 (9.9%)	79 (12.9%)	13 (6.2%)	54 (12.1%)	28 (12.3%)	554 (11.3%)
Race									
White	1289 (93.8%)	1087 (93.1%)	324 (95.0%)	488 (92.8%)	565 (92.3%)	203 (96.2%)	406 (90.8%)	209 (92.1%)	4571 (93.2%)
Black/AA	10 (0.7%)	7 (0.6%)	1 (0.3%)	8 (1.5%)	4 (0.7%)	0 (0.0%)	6 (1.3%)	0 (0.0%)	36 (0.7%)
Asian	8 (0.6%)	10 (0.9%)	0 (0.0%)	6 (1.1%)	5 (0.8%)	1 (0.5%)	5 (1.1%)	2 (0.9%)	37 (0.8%)
More than one race	8 (0.6%)	11 (0.9%)	2 (0.6%)	2 (0.4%)	3 (0.5%)	1 (0.5%)	4 (0.9%)	1 (0.4%)	32 (0.7%)
Unknown/Unsure	59 (4.3%)	52 (4.5%)	14 (4.1%)	22 (4.2%)	35 (5.7%)	6 (2.8%)	26 (5.8%)	15 (6.6%)	229 (4.7%)
Any Blood Specimen									
No	114 (8.3%)	62 (5.3%)	24 (7.0%)	40 (7.6%)	54 (8.8%)	16 (7.6%)	43 (9.6%)	15 (6.6%)	368 (7.5%)
Yes	1260 (91.7%)	1105 (94.7%)	317 (93.0%)	486 (92.4%)	558 (91.2%)	195 (92.4%)	404 (90.4%)	212 (93.4%)	4537 (92.5%)
DNA (extracted)									
No	151 (11.0%)	83 (7.1%)	39 (11.4%)	58 (11.0%)	80 (13.1%)	21 (10.0%)	60 (13.4%)	20 (8.8%)	512 (10.4%)
Yes	1222 (89.0%)	1084 (92.9%)	302 (88.6%)	467 (89.0%)	532 (86.9%)	190 (90.0%)	387 (86.6%)	206 (91.2%)	4390 (89.6%)
Buffy Coat (banked)									
No	547 (39.8%)	491 (42.1%)	118 (34.6%)	205 (39.0%)	234 (38.2%)	73 (34.6%)	175 (39.1%)	78 (34.4%)	1921 (39.2%)
Yes	827 (60.2%)	676 (57.9%)	223 (65.4%)	321 (61.0%)	378 (61.8%)	138 (65.4%)	272 (60.9%)	149 (65.6%)	2984 (60.8%)
Serum									
No	226 (16.4%)	208 (17.8%)	50 (14.7%)	83 (15.8%)	119 (19.4%)	31 (14.7%)	91 (20.4%)	43 (18.9%)	851 (17.3%)
Yes	1148 (83.5%)	959 (82.2%)	291 (85.3%)	443 (84.3%)	493 (80.5%)	180 (85.3%)	356 (79.6%)	184 (81.1%)	4054 (82.7%)

Plasma									
No	275 (20.0%)	157 (13.5%)	45 (13.2%)	87 (16.5%)	123 (20.1%)	34 (16.1%)	102 (22.8%)	50 (22.0%)	873 (17.8%)
Yes	1099 (80.0%)	1010 (86.6%)	296 (86.8%)	439 (83.5%)	489 (79.9%)	177 (83.9%)	345 (77.2%)	177 (78.0%)	4032 (82.2%)
On Tissue Microarray									
No	1017 (74.1%)	638 (54.7%)	221 (64.8%)	356 (67.8%)	558 (91.2%)	202 (95.7%)	349 (78.1%)	140 (61.9%)	3481 (71.0%)
Yes	356 (25.9%)	529 (45.3%)	120 (35.2%)	169 (32.2%)	54 (8.8%)	9 (4.3%)	98 (21.9%)	86 (38.1%)	1421 (29.0%)
Enrollment Qx Completed									
No	453 (33.0%)	309 (26.5%)	95 (27.9%)	131 (24.9%)	158 (25.8%)	58 (27.5%)	133 (29.8%)	70 (30.8%)	1407 (28.7%)
Yes	921 (67.0%)	858 (73.5%)	246 (72.1%)	395 (75.1%)	454 (74.2%)	153 (72.5%)	314 (70.2%)	157 (69.2%)	3498 (71.3%)
Risk Factor Qx Completed (only Mayo participants eligible)									
No	693 (50.4%)	460 (39.4%)	150 (44.0%)	220 (41.8%)	292 (47.7%)	110 (52.1%)	243 (54.4%)	113 (49.8%)	2281 (46.5%)
Yes	681 (49.6%)	707 (60.6%)	191 (56.0%)	306 (58.2%)	320 (52.3%)	101 (47.9%)	204 (45.6%)	114 (50.2%)	2624 (53.5%)
Any Follow-up Qx Completed									
No	417 (30.3%)	224 (19.2%)	95 (27.9%)	107 (20.3%)	153 (25.0%)	75 (35.5%)	171 (38.3%)	63 (27.8%)	1305 (26.6%)
Yes	957 (69.7%)	943 (80.8%)	246 (72.1%)	419 (79.7%)	459 (75.0%)	136 (64.5%)	276 (61.7%)	164 (72.2%)	3600 (73.4%)
Participant Status									
Deceased	581 (42.3%)	298 (25.5%)	182 (53.4%)	119 (22.6%)	234 (38.2%)	120 (56.9%)	223 (49.9%)	95 (41.9%)	1852 (37.8%)
Active follow-up	617 (44.9%)	676 (57.9%)	122 (35.8%)	303 (57.6%)	275 (44.9%)	71 (33.6%)	159 (35.6%)	107 (47.1%)	2330 (47.5%)
Passive follow-up	153 (11.1%)	175 (15.0%)	30 (8.8%)	95 (18.1%)	94 (15.4%)	20 (9.5%)	57 (12.8%)	22 (9.7%)	646 (13.2%)
Withdrawal, keep samples	3 (0.2%)	5 (0.4%)	1 (0.3%)	3 (0.6%)	2 (0.3%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	15 (0.3%)
Withdrawal, discard samples	0 (0.0%)	1 (0.1%)	1 (0.3%)	1 (0.2%)	2 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.1%)
Lost to follow-up	20 (1.5%)	12 (1.0%)	5 (1.5%)	5 (1.0%)	5 (0.8%)	0 (0.0%)	7 (1.6%)	3 (1.3%)	57 (1.2%)
Current Age for Alive Patients									
Mean (SD)	67.5 (15.31)	68.4 (12.34)	71.6 (10.20)	71.2 (12.11)	68.3 (14.61)	64.1 (13.29)	62.1 (16.38)	70.4 (11.64)	68.2 (13.84)
Median	69	69	72	72	69	67	64	70	69
IQR	58.0, 79.0	60.0, 78.0	65.0, 78.0	64.0, 79.0	61.0, 78.0	56.0, 72.0	50.0, 74.0	63.0, 79.0	60.0, 78.0
Range	25.0, 100.0	28.0, 98.0	41.0, 93.0	28.0, 99.0	25.0, 99.0	26.0, 95.0	26.0, 101.0	31.0, 94.0	25.0, 101.0
Primary COD, n (%)									
Due to lymphoma	285 (56.8%)	85 (37.0%)	88 (57.9%)	20 (22.2%)	101 (54.6%)	65 (59.6%)	116 (60.1%)	41 (52.6%)	801 (52.0%)
Due to therapy - infection	24 (4.8%)	16 (7.0%)	10 (6.6%)	2 (2.2%)	10 (5.4%)	3 (2.8%)	19 (9.8%)	5 (6.4%)	89 (5.8%)
Due to therapy - cardiac	7 (1.4%)	5 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	13 (0.8%)
Due to therapy - other	12 (2.4%)	13 (5.6%)	4 (2.7%)	4 (4.4%)	5 (2.7%)	3 (2.8%)	4 (2.1%)	2 (2.6%)	47 (3.0%)
Second primary malignancy	41 (8.2%)	39 (17.0%)	8 (5.3%)	10 (11.1%)	13 (7.0%)	10 (9.2%)	7 (3.6%)	7 (9.0%)	135 (8.8%)

Due to other causes	88 (17.5%)	46 (20.0%)	20 (13.2%)	38 (42.2%)	44 (23.8%)	17 (15.6%)	22 (11.4%)	16 (20.5%)	291 (18.9%)
Unable to obtain records	45 (9.0%)	26 (11.3%)	22 (14.5%)	16 (17.8%)	12 (6.5%)	11 (10.1%)	24 (12.4%)	7 (9.0%)	163 (10.6%)
EFS Event									
Yes	682 (49.6%)	670 (57.4%)	245 (71.8%)	256 (48.6%)	332 (54.2%)	140 (66.4%)	281 (62.9%)	134 (59.0%)	2740 (55.9%)
EFS Component									
Progression/relapse/transformation	361 (52.9%)	540 (80.6%)	133 (54.3%)	136 (53.1%)	166 (50.0%)	63 (45.0%)	128 (45.6%)	80 (59.7%)	1607 (58.6%)
Retreatment	38 (5.6%)	23 (3.4%)	56 (22.9%)	38 (14.8%)	55 (16.6%)	11 (7.9%)	50 (17.8%)	14 (10.4%)	285 (10.4%)
Lymphoma Death	86 (12.6%)	14 (2.1%)	21 (8.6%)	16 (6.3%)	34 (10.2%)	22 (15.7%)	53 (18.9%)	12 (9.0%)	258 (9.4%)
Other Death	197 (28.9%)	93 (13.9%)	35 (14.3%)	66 (25.8%)	77 (23.2%)	44 (31.4%)	50 (17.8%)	28 (20.9%)	590 (21.5%)
Second Cancer Dx, n (%)									
No	1224 (89.1%)	994 (85.2%)	288 (84.5%)	453 (86.1%)	550 (89.9%)	187 (88.6%)	407 (91.1%)	189 (83.3%)	4292 (87.5%)
Yes	150 (10.9%)	173 (14.8%)	53 (15.5%)	73 (13.9%)	62 (10.1%)	24 (11.4%)	40 (8.9%)	38 (16.7%)	613 (12.5%)
